Parenteral artemisinins are associated with reduced mortality and neurologic deficits and improved long-term behavioral outcomes in children with severe malaria

BACKGROUND: In 2011, the World Health Organization recommended injectable artesunate as the first-line therapy for severe malaria (SM) due to its superiority in reducing mortality compared to quinine. There are limited data on long-term clinical and neurobehavioral outcomes after artemisinin use for...

Descripción completa

Detalles Bibliográficos
Autores principales: Conroy, Andrea L., Opoka, Robert O., Bangirana, Paul, Namazzi, Ruth, Okullo, Allen E., Georgieff, Michael K., Cusick, Sarah, Idro, Richard, Ssenkusu, John M., John, Chandy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317420/
https://www.ncbi.nlm.nih.gov/pubmed/34315456
http://dx.doi.org/10.1186/s12916-021-02033-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317420/
https://www.ncbi.nlm.nih.gov/pubmed/34315456
http://dx.doi.org/10.1186/s12916-021-02033-1

Ejemplares similares